E Hellström-Lindberg - JoVE Visualize

Showing results (31-40 of 39) with videos related to

Pageof 4

Sort By:

You have reached the last page of results.This site can display upto 39 results.

Bone Marrow Transplantation|November 9, 2004

Stem cell transplantation from identical twins in patients with myelodysplastic syndromesN Kröger, R Brand, A van Biezen, et al.

Ecancermedicalscience|January 26, 2012

The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an updateL R Silverman, P Fenaux, G J Mufti, et al.

Leukemia|December 6, 2005

Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survivalG Juliusson, R Billström, A Gruber, et al.

Ecancermedicalscience|January 26, 2012

Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an updateP Fenaux, G J Mufti, E Hellström-Lindberg, et al.

Blood Cancer Journal|March 11, 2014

Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trialM Tobiasson, I Dybedahl, M S Holm, et al.

Blood|November 9, 2018

Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trialsU Platzbecker, P Fenaux, L Adès, et al.

Blood|June 25, 1998

Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patientsE Hellström-Lindberg, T Ahlgren, Y Beguin, et al.

Journal of Internal Medicine|December 8, 2016

Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndromeH K G Garelius, W T Johnston, A G Smith, et al.

Leukemia|September 13, 2003

No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative diseaseR Hast, E Hellström-Lindberg, L Ohm, et al.

Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:

Pageof 4

You have reached the last page of results.This site can display upto 39 results.

Bone Marrow Transplantation|November 9, 2004

Stem cell transplantation from identical twins in patients with myelodysplastic syndromesN Kröger, R Brand, A van Biezen, et al.

Ecancermedicalscience|January 26, 2012

The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an updateL R Silverman, P Fenaux, G J Mufti, et al.

Leukemia|December 6, 2005

Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survivalG Juliusson, R Billström, A Gruber, et al.

Ecancermedicalscience|January 26, 2012

Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an updateP Fenaux, G J Mufti, E Hellström-Lindberg, et al.

Blood Cancer Journal|March 11, 2014

Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trialM Tobiasson, I Dybedahl, M S Holm, et al.

Blood|November 9, 2018

Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trialsU Platzbecker, P Fenaux, L Adès, et al.

Blood|June 25, 1998

Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patientsE Hellström-Lindberg, T Ahlgren, Y Beguin, et al.

Journal of Internal Medicine|December 8, 2016

Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndromeH K G Garelius, W T Johnston, A G Smith, et al.

Leukemia|September 13, 2003

No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative diseaseR Hast, E Hellström-Lindberg, L Ohm, et al.

Pageof 4